Last reviewed · How we verify
Mixed Epilepsy
Approved treatments
- Tegretol · Novartis AG (originally Geigy)
Carbamazepine reduces polysynaptic responses and blocks post-tetanic potentiation, potentially alleviating seizures and pain. - Carbamazepin · Enanta Pharmaceuticals, Inc
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Mixed Epilepsy patent landscape — cliff calendar, originator estates, attackable patents
- Mixed Epilepsy treatment landscape brief
- Mixed Epilepsy treatment updates RSS
Frequently asked questions about Mixed Epilepsy
What drugs treat Mixed Epilepsy?
Tracked treatments include Tegretol, Carbamazepin.
What is the treatment for Mixed Epilepsy?
Standard treatment for Mixed Epilepsy includes Tegretol, Carbamazepin. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Mixed Epilepsy patent cliff · Mixed Epilepsy CI report
- Treatment: Tegretol · Novartis AG (originally Geigy)
- Treatment: Carbamazepin · Enanta Pharmaceuticals, Inc
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing